Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.43
+0.16 (3.04%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
1.34B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Monte Rosa Therapeutics | 181.54M |
| Immatics | 56.67M |
| EyePoint | 31.37M |
| Septerna | 22.05M |
| Zenas BioPharma | 15.00M |
| Taysha Gene Therapies | 6.31M |
| AtaiBeckley | 4.09M |
SVRA News
- 3 days ago - Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 5 days ago - Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
- 17 days ago - Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 24 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 4 weeks ago - Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
- 5 weeks ago - Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Business Wire
- 7 weeks ago - Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Business Wire